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blood progenitors and that infusion of expanded cells together with
a non-cultured cord blood unit will likely provide rapid engraft-
ment by the former cells and still allow for stable long-term
engraftment by the latter cells. The potential efﬁcacy of Delta1-
cultured CB progenitors in contributing to rapid early engraftment
in clinical CBT is currently being tested in a Phase I clinical trial.
To date, two patients with hematologic malignancy (AML) have
received Delta1-cultured CB cells with a second unrelated and
unmanipulated donor CB graft after undergoing a myeloablative
preparative regimen with cytoxan, total body irradiation and ﬂu-
darabine, and post grafting immunosuppression with cyclosporin
and MMF. Upon harvest of the cultured cells at 16 days post
culture initiation, the CD34 fold expansion was 210 and 174 and
the fold expansion of total cell numbers, 791 and 740. The kinetics
and durability of hematopoietic reconstitution and the relative
contribution of the expanded and non-manipulated grafts over
time will be determined by chimerism analysis in the marrow
(unsorted) and peripheral blood CD3, CD33, CD56, CD14 and
CD19 cell fractions, beginning on day 7 post transplant. Prelim-
inary data from the ﬁrst 2 patients demonstrated early myeloid
recovery at a time when engraftment due to infusion of 2 non-
cultured units would not be expected, with both patients achieving
an ANC of 100 by day7 post transplant. Engraftment (deﬁned as
the ﬁrst of three consecutive days with an ANC 500) was
achieved at day 9 and day 16, which compares favorably to our
own center’s data demonstrating a median time to engraftment of
27 days (N10) following conventional double unmanipulated
CBT and published results reporting a median time to engraftment
of 23 days (Barker, J et al, Blood, 105(3):1343-1347, Feb 2005).
Furthermore, the early myeloid engraftment seen in these patients
was determined to be 100% derived from the expanded CB graft.
Continued analysis of peripheral blood sorted cell fractions re-
vealed loss of contribution to engraftment in all cell populations
from the expanded cells by day 21 in the ﬁrst patient. In contrast,
the second patient continued to show contribution of engraftment
in the CD14, CD56 and CD19 sorted cell fractions at day 100 post
transplant. Furthermore, the patients treated to date have also
experienced a reduction in the expected regimen related toxicities
(e.g., mucositis, fevers, need for nutritional support), and the sec-
ond patient was discharged from the hospital on day 15 post
transplant. These two patients provide compelling data that clini-
cally relevant expansion of at least a short term repopulating cell is
feasible and may result in signiﬁcant decrease in delayed engraft-
ment post CBT and potentially a reduction of regimen related
toxicities.
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TRANSPLANTATION OF EX VIVO EXPANDED CORD BLOOD
Elizabeth J. Shpall, Simon Robinson, Marcos de Lima, Krishna Kom-
anduri, John D. McMannis, Laurence Cooper, Laura Worth, Chitra
Hosing, Ian K. McNiece,* Richard E. Champlin The MD Anderson
Department of Stem Cell Transplantation and Cellular Therapy, Hous-
ton, Texas and the Johns Hopkins Oncology Center, Baltimore, MD*
Cord blood (CB) is rapidly becoming an important source of
hematopoietic stem and progenitor cells (HSPC) for transplant for
cancer patients. Advantages associated with the use of CB include
the ready availability, increased ethnic diversity of the tissue (ethnic
minorities are poorly represented in current blood and bone mar-
row registries) and a reduced risk of graft-versus-host disease
(GvHD) at transplant. One major disadvantage associated with the
use of CB is delayed platelet and myeloid engraftment observed
following transplant when compared to the transplant of growth
factor-mobilized peripheral blood (mPB) or bone marrow (BM)
HSPC. Delayed engraftment is thought to be due, at least in part,
to the relatively low cell dose available for transplant and limits
effective CB transplantation to patients 70 kg. There also appear
to be intrinsic differences between CB-derived and peripheral
blood or bone marrow-derived HSPC, which may also contribute
to delayed engraftment. An approach for ex vivo expansion is the
co-culture of CB cells with bone marrow mesenchymal stem cells
(MSCs) which provide a microenvironment for the complex mo-
lecular cues that direct self-renewal/proliferation and regulate the
differentiation and maturation of hematopoietic progeny. Mc-
Niece et al have reported impressive expansion of CB on MSC
stroma. Robinson et al have shown superior expansion of CB in
MSC co-cultures when compared to liquid cultures of the same
CD133 CB fractions. Infusion of MSCs has been shown to
promote engraftment of human CD34 cells in NOD/SCID mice
and fetal sheep. Importantly MSC have been shown to have im-
munomodulatory activity which may reduce graft versus host dis-
ease and enhance engraftment in patients. In pre-clinical studies
performed by Robinson et al at MD Anderson, MSCs were isolated
from bone marrow mononuclear cells and conﬂuent monolayers
generated in 175 cm2 tissue culture ﬂasks. The monolayers were
maintained by a weekly medium change with MSC culture medium
until ready for use. At least 3 passages performed to ensure removal
of residual donor hematopoiesis. Non-selected, washed, CB sam-
ples were diluted in ex vivo expansion medium containing 20%
(v/v) FBS (HyClone) plus 100ng/ml each of G-CSF (Amgen), SCF
(R&D Systems, Minneapolis, MN) and thrombopoietin (TPO)
(R&D Systems) and plated over the pre-established conﬂuent
MSC monolayers. Speciﬁcally, cord blood cells were plated as a
10% fraction and placed in 50 mls of ex vivo expansion medium
over pre-established conﬂuent MSC monolayers in 175 cm2 tissue
culture ﬂasks. After 7 days at 37°C, non-adherent cells were re-
moved and a proportion diluted 1:15 for subsequent culture in ex
vivo expansion medium in either 75 cm2 tissue culture ﬂasks or
1-liter Teﬂon-coated culture bags (American Fluoroseal Corp.) for
an additional 7 days (14 days total). The original co-culture ﬂasks
(containing the MSC) were re-fed with 50 mls of expansion me-
dium and also cultured for an additional 7 days. At day 14, non-
adherent cells from both cultures were harvested and assayed for
yield of TNC, CFU, CD133, CD34 and CAFCwk2-6 data.
The liquid culture method employing CD133 CB currently
being studied clinically at MD Anderson was compared to the
MSC-cord blood co culture technique. The yield of total nucleated
cells, CFU, CD34 and CD133 cells as well as CAFCwk2-6 in
the CB-MSC co-culture method was signiﬁcantly higher than that
of the current liquid culture method. These data suggest that
MSC-cord blood could potentially produce more rapid engraft-
ment than the liquid expansion methods.
MD Anderson Mesenchymal Stem Cell - Cord Expansion Pro-
tocol #05-0781 (IND 13, 034). Based on the data described above,
a clinical trial will be conducted. In this study a family member will
serve as the marrow-derived mesenchymal stem cell (MSC) donor
for this trial; 50 ml of marrow will be aspirated from that donor and
the MSCs generated in 10 ﬂasks (takes 21 days). One of two
designated CB units will then be thawed and placed into the ﬂasks
containing the conﬂuent layers of MSCS with the growth factor
regimen used in our current liquid culture protocol (SCF, FLT3,
G-CSF and TPO). After 7 days at 37°C, the non-adherent cells
will be removed from each ﬂask, placed into each of ten 1-liter
Teﬂon-coated culture bags and cultured for an additional 7 days
(14 days total). Patients will be admitted to the hospital on day -9
for hydration and receive the designated preparative regimen on
days8 through2. On day 0, the unmanipulated CB unit will be
infused in the morning followed by the expanded CB cells (from
the bags and the remaining CB-MSCs in the ﬂasks). This is a
single-arm study with an accrual target of 35-40 patients. The
primary endpoint of the trial is time to engraftment. Accrual is
planned to begin in May, 2007.
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THERAPEUTIC MANIPULATION OF THE STEM CELL NICHE
David Scadden, MD Harvard Stem Cell Institute, Massachusetts Gen-
eral Hospital, Boston, MA
Altering stem cell function in normal and disease settings has
implications for regenerative medicine and for the current practice
of stem cell transplantation. Emphasis has generally been placed on
the stem cell as a cell autonomous unit, however in vivo these cells
are clearly responsive to distinct physiologic cues provided by their
microenvironment. The ability of speciﬁc anatomic sites to provide
regulatory input is what deﬁnes these sites as stem cell niches and
offers a distinct set of targets for developing stem cell based
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